Literature DB >> 5544494

Prevention of experimental allergic encephalomyelitis with cobra venom factor.

H Pabst, N K Day, H Gewurz, R A Good.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5544494     DOI: 10.3181/00379727-136-35310

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


× No keyword cloud information.
  7 in total

1.  Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation.

Authors:  S Piddlesden; H Lassmann; I Laffafian; B P Morgan; C Linington
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

2.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

3.  Brain damage complicating septic shock: acute haemorrhagic leucoencephalitis as a complication of the generalised Shwartzman reaction.

Authors:  D I Graham; P O Behan; I A More
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-01       Impact factor: 10.154

4.  Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis.

Authors:  C Linington; H Lassmann; B P Morgan; D A Compston
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 5.  Role and mechanism of action of complement in regulating T cell immunity.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Mol Immunol       Date:  2010-06-18       Impact factor: 4.407

6.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

Review 7.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.